BUZZ-Evommune surges in NYSE debut after $150 million IPO

Reuters

Nov 07, 2025

BUZZ-<a href="https://laohu8.com/S/EVMN">Evommune</a> surges in NYSE debut after $150 million IPO

** Drug developer Evommune's EVMN.N shares jump as much as 26.1% in their NYSE debut

** Stock opened at $17.25 apiece vs $16 IPO price; last up 19.8% at $19.18

** EVMN sold ~9.4 million shares within the marketed range of $15 and $17 apiece to raise $150 million

** Palo Alto, California-based EVMN is developing therapies to treat chronic inflammatory diseases such as eczema and hives

** Among its drug pipeline, EVMN currently has two experimental treatments, EVO756 and EVO301, in mid-stage trials

** EVMN is the third notable U.S. biotech to go public since September, as drug developer IPOs make a comeback after a months-long freeze

** Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor were joint book-running managers for the offering

(Reporting by Arasu Kannagi Basil in Bengaluru)

((ArasuKannagi.Basil@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581115160"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581115160\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581115160?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 03:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581115160","market":"fut","top_or_hot":-1,"title":"BUZZ-Evommune surges in NYSE debut after $150 million IPO","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/EVMN\">Evommune</a> surges in NYSE debut after $150 million IPO</title></head><body><p>** Drug developer Evommune's <span>EVMN.N</span> shares jump as much as 26.1% in their NYSE debut</p><p>** Stock opened at $17.25 apiece vs $16 IPO price; last up 19.8% at $19.18</p><p>** EVMN sold ~9.4 million shares within the marketed range of $15 and $17 apiece to raise $150 million</p><p>** <a href=\"https://laohu8.com/S/PANW\">Palo Alto</a>, California-based EVMN is developing therapies to treat chronic inflammatory diseases such as eczema and hives</p><p>** Among its drug pipeline, EVMN currently has two experimental treatments, EVO756 and EVO301, in mid-stage trials</p><p>** EVMN is the third notable U.S. biotech to go public since September, as drug developer IPOs make a comeback after a months-long freeze</p><p>** <a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a>, Leerink Partners, <a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI, and Cantor were joint book-running managers for the offering</p><p>(Reporting by Arasu Kannagi Basil in Bengaluru)</p><p>((ArasuKannagi.Basil@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Evommune surges in NYSE debut after $150 million IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Evommune surges in NYSE debut after $150 million IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 03:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/EVMN\">Evommune</a> surges in NYSE debut after $150 million IPO</title></head><body><p>** Drug developer Evommune's <span>EVMN.N</span> shares jump as much as 26.1% in their NYSE debut</p><p>** Stock opened at $17.25 apiece vs $16 IPO price; last up 19.8% at $19.18</p><p>** EVMN sold ~9.4 million shares within the marketed range of $15 and $17 apiece to raise $150 million</p><p>** <a href=\"https://laohu8.com/S/PANW\">Palo Alto</a>, California-based EVMN is developing therapies to treat chronic inflammatory diseases such as eczema and hives</p><p>** Among its drug pipeline, EVMN currently has two experimental treatments, EVO756 and EVO301, in mid-stage trials</p><p>** EVMN is the third notable U.S. biotech to go public since September, as drug developer IPOs make a comeback after a months-long freeze</p><p>** <a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a>, Leerink Partners, <a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI, and Cantor were joint book-running managers for the offering</p><p>(Reporting by Arasu Kannagi Basil in Bengaluru)</p><p>((ArasuKannagi.Basil@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2089283258.USD","symbol_name":"安联环球可持续基金Cl AM Dis","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL6N3WI123:1","article_id":"2581115160","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581115160","pubTimestamp":1762455978,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Evommune surges in NYSE debut after $150 million IPO** Drug developer Evommune's EVMN.N shares jump as much as 26.1% in their NYSE debut** Stock opened at $17.25 apiece vs $16 IPO price; last up 19.8% at $19.18** EVMN sold ~9.4 million shares within the marketed range of $15 and $17 apiece to raise $150 million** Palo Alto, California-based EVMN is developing therapies to treat chronic inflammatory diseases such as eczema and hives** Among its drug pipeline, EVMN currently has two experimental treatments, EVO756 and EVO301, in mid-stage trials** EVMN is the third notable U.S. biotech to go public since September, as drug developer IPOs make a comeback after a months-long freeze** Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor were joint book-running managers for the offering","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0971096721.USD":"富达环球金融服务 A","LU1548497426.USD":"安联环球人工智能AT Acc","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","EVR":"Evercore","BK4207":"综合性银行","LU0106831901.USD":"贝莱德世界金融基金A2","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4581":"高盛持仓","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","MNSH":"MNSN HLDGS INC.","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","BK4127":"投资银行业与经纪业","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","BK4516":"特朗普概念","EVMN":"Evommune","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4504":"桥水持仓","LU0557290698.USD":"施罗德环球可持续增长基金","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC"},"translate_title":"BUZZ-Evommune在1.5亿美元IPO后在纽约证券交易所上市，股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVR":0.9,"MNSH":0.9,"EVMN":0.9},"content_text":"BUZZ-Evommune surges in NYSE debut after $150 million IPO** Drug developer Evommune's EVMN.N shares jump as much as 26.1% in their NYSE debut** Stock opened at $17.25 apiece vs $16 IPO price; last up 19.8% at $19.18** EVMN sold ~9.4 million shares within the marketed range of $15 and $17 apiece to raise $150 million** Palo Alto, California-based EVMN is developing therapies to treat chronic inflammatory diseases such as eczema and hives** Among its drug pipeline, EVMN currently has two experimental treatments, EVO756 and EVO301, in mid-stage trials** EVMN is the third notable U.S. biotech to go public since September, as drug developer IPOs make a comeback after a months-long freeze** Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor were joint book-running managers for the offering(Reporting by Arasu Kannagi Basil in Bengaluru)((ArasuKannagi.Basil@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}